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Originally mistaken as an opioid receptor, the sigma-1 receptor (Sig1R) is a ubiquitous
membrane protein that has been involved in many cellular processes. While the precise
function of Sig1R has long remained mysterious, recent studies have shed light on its role
and the molecular mechanisms triggered. Sig1R is in fact a stress-activated chaperone
mainly associated with the ER-mitochondria interface that can regulate cell survival
through the control of calcium homeostasis. Sig1R functionally regulates ion channels
belonging to various molecular families and it has thus been involved in neuronal plasticity
and central nervous system diseases. Interestingly, Sig1R is frequently expressed in
tumors but its function in cancer has not been yet clarified. In this review, we discuss
the current understanding of Sig1R. We suggest herein that Sig1R shapes cancer cell
electrical signature upon environmental conditions. Thus, Sig1R may be used as a novel
therapeutic target to specifically abrogate pro-invasive functions of ion channels in cancer
tissue.
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INTRODUCTION
The concept of “Sigma receptors” arose 40 years ago in a pharma-
cological study postulating the existence of three types of opioid
receptors on the basis of the psychomimetic effects induced by
several opioid compounds (μ, κ and σ receptor respectively
accounting for the effects produced by morphine, ketacyclazocine
and SKF 10,047) (Martin et al., 1976). Further pharmacologi-
cal studies revealed the existence of two binding sites, namely
Sigma 1 (Sig1R) and Sigma 2 receptors (Sig2R) (Quirion et al.,
1992). The Sig1R was cloned in 1996 (gene names: SIGMAR1 or
OPRS1) and the gene is located on 9p13 (Hanner et al., 1996;
Prasad et al., 1998). Sig1R is a 25-kDa protein anchored in the
endoplasmic reticulum (ER) with no similarity with other known
mammalian proteins, thus definitely ruling out any connection
with a classical receptor family. Sig1R possesses two transmem-
brane regions and two steroid binding domains (SBD). These
domains form a pocket which is the binding site for choles-
terol, steroids, sphingolipids (Palmer et al., 2007; Fontanilla
et al., 2008), and also for a wide panel of synthetic or natu-
ral compounds (sigma ligands) from different classes such as
opioids, antipsychotics, psychostimulants, alkaloids or antide-
pressants (Pal et al., 2008; Maurice and Su, 2009) (Figure 1).
In vivo, endogenous dimethyl tryptamine (DMT) interacts with
Sig1R in the brain but its physiological significance as an endoge-
nous sigma ligand is not yet clarified (Fontanilla et al., 2009;
Mavlyutov et al., 2012).
The molecular nature of Sig2R has long been questioned. A
recent work proposed the progesterone receptor membrane com-
ponent 1 (Pgrmc1) as the putative sigma 2 binding site (Xu
et al., 2011). This cytochrome-related protein binds several P450
proteins and various chemical compounds and it participates to
cholesterol synthesis. However, while this putative Sig2R shares
some pharmacological properties with Sig1R, the two proteins
belong to distinct families. This review will focus on Sig1R.
Sig1Rs have been associated with many diseases includ-
ing stroke, cocaine addiction, Alzheimer’s disease, amnesia,
amyotrophic lateral sclerosis, retinal degeneration, and cancer
(Romieu et al., 2004; Aydar et al., 2006; Renaudo et al., 2007;
Maurice and Su, 2009; Luty et al., 2010; Mavlyutov et al., 2011;
Ruscher et al., 2011; Kourrich et al., 2013). Nonetheless, the way
Sig1R operates in such diseases is still poorly understood. Su and
colleagues’work on neurons and CHO cells have shed light on
the molecular mechanisms underlying Sig1R functions. Sig1R is
mainly located at the ER, in close contact with the mitochon-
dria, in the so-called mitochondria-associated-ER membrane
domains (MAM). In resting condition, Sig1R resides in ceramide-
and cholesterol-rich lipid microdomains associated with the ER-
resident chaperone GRP78 (BiP) (Hayashi and Su, 2007; Hayashi
and Fujimoto, 2010). Under cellular stress leading to ER injury,
Sig1R dissociates from BiP and binds IP3 receptors, enhancing
in turn cell survival through the control of calcium signaling
between the ER andmitochondria. In addition, Sig1R translocates
to other cell compartments and binds to different membrane
proteins. The stimulation with sigma “agonists” mimicks stress-
induced Sig1R dissociation from BiP and Sig1R delocalization,
while sigma ligands classified as “antagonists” impede this pro-
cess (Hayashi and Su, 2007). Altogether, these results have led to
a model in which Sig1R is “silent” in normal physiological condi-
tions, whereas in case of a disease, Sig1R behaves as a chaperone
that binds client protein to the benefit of cell survival (Su et al.,
2010). This exciting hypothesis has been validated by recent stud-
ies demonstrating that Sig1R molecular silencing reduces brain
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FIGURE 1 | Model of the sigma-1 receptor binding region from
previous photolabeling studies. The shaded area represents the ligand
binding region. Adapted with permission from Chu et al. (2013).
recovery after experimental stroke (Ruscher et al., 2011) and pro-
motes retina degeneration after acute damage to the optic nerve
(Mavlyutov et al., 2011).
The question of client proteins targeted by Sig1R is of impor-
tance. Beyond the coupling with IP3 receptors, a number of
studies mainly based on the effects of exogenous sigma ligands
have shown that Sig1R interferes with dopamine and acetyl-
choline systems and modulates the function of ion channels
belonging to various families. Recent studies have described a
molecular interaction between Sig1R and ion channels, suggest-
ing that ion channels represent a major client protein family
for the Sig1R chaperone (Carnally et al., 2010; Crottes et al.,
2011; Balasuriya et al., 2012; Kourrich et al., 2012). Over the past
decades, ion channels have been integrated to the main cellu-
lar processes underlying the hallmarks of cancer: tumors often
express ion channels and transporters that are absent from the
corresponding tissue. It is suggested that these channels and
transporters enhance the cell’s capacity to adapt themselves to
restraint metabolic conditions encountered within the tumor tis-
sue (low pH and PO2, poor nutrient supply, etc. . . ) (Wulff et al.,
2009; Prevarskaya et al., 2010; Arcangeli, 2011). Transport pro-
teins therefore participate to the adaptive cancer cells’response
to environmental stress, conferring them with greater aggressive-
ness. This review attempts to draw together the knowledge about
ion channel regulation by Sig1R and the recent discoveries on the
function of ion channels in cancer. We suggest that upon envi-
ronmental challenging conditions within the tumor, Sig1R may
participate in the electrical remodeling of cancer cell electrical
properties to enhance their survival and aggressiveness.
SIGMA 1 RECEPTORS IN CANCER
Binding experiment studies realized in the 90’s revealed that
sigma receptors are highly expressed in many human and
rodent tumor cell lines including breast, lung, prostate, colon,
melanoma, neuroblastoma and glioma (John et al., 1995; Vilner
et al., 1995b; Aydar et al., 2004). However, most of the sigma
ligands used in these studies are not selective enough between
Sig1R and Sig2R to draw a definitive conclusion on the density
of each binding site in the explored cancer cell types. Using a
specific Sig1R antibody, a high expression of Sig1R was found
in lung, breast and prostate cancer cell lines whereas low levels
were found in normal counterpart cells. Interestingly, the Sig1R
density was increased in high metastatic potential cancer cells
suggesting a link between Sig1R expression and aggressiveness
(Aydar et al., 2006). In another study, the expression of Sig1R
was explored by imunohistochemistry in 58 breast cancer patients
and 51 normal breasts. Sig1R positive epithelial cell staining was
detected in 60 or 41% of invasive or in situ cancers respec-
tively, in 75% of ductal hyperplasia and in 33% of normal breast
(Wang et al., 2004). Accordingly, scintigraphy with a moderately-
selective Sig1R ligand (N-[2-(1′-Piperidinyl) Ethyl]-3-123I-Iodo-
4-Methoxybenzamide) on patients with primary breast cancer
revealed that the ligand was specifically retained within the tumor
site, but not in healthy tissues (Caveliers et al., 2001). Several
reports indicate that the use of Sig1R ligands to target therapeu-
tic nanoparticles dramatically enhances the delivery of siRNA or
drugs at the tumor site in melanoma, prostate, lung and breast
cancer (Li and Huang, 2006; Chen et al., 2010; Guo et al., 2012;
Kim and Huang, 2012).
Altogether, these studies strongly suggest that Sig1R is over
expressed in many cancer cells and an extensive exploration of
Sig1R expression in biopsies from various cancers is now required
to determine whether Sig1R could be proposed as a diagnosis or
prognosis marker.
The effects of sigma ligands on cancer cells’ behavior have
been assessed by many groups in vitro and in vivo. Early descrip-
tive works showed that cell treatment with sigma ligands causes
rounding, detachment and growth inhibition of C6 glioma
(Vilner et al., 1995a), breast and colon carcinoma and melanoma
cells (Brent and Pang, 1995; Aydar et al., 2004). Further works by
Spruce and coll. showed that the moderately selective ligand rim-
cazole provokes in vitro and in vivo (mouse xenograft model) a
tumor-selective, caspase-dependent apoptosis of breast and colon
cancer (Spruce et al., 2004; Achison et al., 2007). Rimcazole was
shown to antagonize a Sig1R-dependent mechanism involving
a calcium-dependent activation of phospholipase C, a calcium-
independent inhibition of phosphatidylinositol 3′-kinase pathway
signaling and the accumulation of HIF-1α. While Sig1R agonists
(+) pentazocine and (+) SKF10,047 had no effect per se, these
ligands could abrogate rimacazole-induced apoptosis, suggesting
that in cancer cells, Sig1R is in an activated state and enhances sur-
vival. In agreement with this hypothesis, transfection of Sig1R in
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HEK293 cells reverses apoptosis induced by the over-expression
of Bax or by staurospaurine (Spruce et al., 2004; Achison et al.,
2007; Crottes et al., 2011). However, whether Sig1R protects can-
cer cells from death through a chaperoning activity has not yet
been addressed.
Sig1R has also been connected to cell/matrix interaction. Aydar
et al. have demonstrated that in breast cancer cells, Sig1R is
associated with β1 integrin in lipid cholesterol-enriched rafts.
Silencing Sig1R with siRNA chased β1 integrin from lipid rafts,
reducing cell adhesion to matrix component such as fibronectin
and vitronectin. Interestingly, treatment with the Sig1R agonist
SKF10,047 also reduced β1 integrin density within lipid rafts and
cell adhesion, an effect that was mimicked by the depletion of
membrane cholesterol by methyl-β-cyclodextrin (Palmer et al.,
2007).
From these data, it is clear that Sig1R participates on sev-
eral facets of cancer cell biology. Recently, mutations in Sig1R
have been found to cause a form of ALS and frontotemporal
lobar degeneration (Luty et al., 2010; Al-Saif et al., 2011; Prause
et al., 2013). Whether mutations in Sig1R also occur in can-
cer tissues is a question that remains to be explored. So far, the
common mechanism by which Sig1R or sigma ligands drives can-
cer cell behavior is not clear. An exciting hypothesis arises from
converging studies describing Sig1R as a sterol-dependent, stress-
activated chaperone controlling lipid raft formation in the ER and
the plasma membrane (PM) [extensively reviewed in Tsai et al.
(2009), Hayashi and Su (2010)]. In response to environmental
conditions encountered in cancer tissue (hypoxia, nutrient and
growth factor deprivation) Sig1Rmay dynamically trigger various
adaptation mechanisms, the nature of which being tightly depen-
dent on the client protein available in a given tumor cell type. At
this stage, it is noteworthy that ion channels emerge from the liter-
ature as the main client protein family for Sig1R (Hayashi and Su,
2007; Crottes et al., 2011; Balasuriya et al., 2012; Kourrich et al.,
2012, 2013).
SIG1R: A MODULATOR OF ION CHANNELS
VOLTAGE-GATED ION CHANNELS
Voltage-gated ion channels (VGIC) are mainly involved in the ini-
tiation and shaping of action potentials and global cell excitability
(Hodgkin andHuxley, 1952; Hille, 1984). The progress made dur-
ing the past decade in characterizing the electrical signature of
cancer cell has intriguingly extended the initial function of VGIC
far beyond the field of exciting cells. Indeed, VGIC are involved in
a number of tumor cell processes including mitosis (Weber et al.,
2006; Becchetti, 2011), migration (Gillet et al., 2009; Becchetti
and Arcangeli, 2010), apoptosis (Lang et al., 2004), adhesion to
ECM (Pillozzi and Arcangeli, 2010), angiogenesis (Pillozzi et al.,
2007), homing and drug resistance (Pillozzi and Arcangeli, 2010).
Interestingly, Sig1R has been shown to interact with K+, Ca2+,
Cl− and Na+ channels (Renaudo et al., 2004; Kourrich et al.,
2012). Very recent studies have provided some clues about these
interactions.
1- Voltage-gated K+ channels (VGKC)
Numerous studies have reported the inhibition of VGKC by sigma
ligands in a wide range of cell types (Kennedy and Henderson,
1990; Soriani et al., 1998, 1999a,b; Lupardus et al., 2000; Kourrich
et al., 2012). In particular, sigma ligands decrease current density
and provoke a leftward shift in the voltage-dependency inactiva-
tion (Zera et al., 1996; Soriani et al., 1999a; Aydar et al., 2002).
In a study performed in frogs’pituitary cells, it was nonetheless
shown that sigma ligands depress the M-current by a right-
ward shift of the activation curve (Soriani et al., 1999b). The
mechanism by which sigma ligands modulate Kv channels has
been proposed to be either direct or indirect, depending on the
model used. Inside-out patch clamp experiments suggested a
direct effect of sigma ligands on Kv channels in rodent neuro-
hypophysal terminals and in small cell lung carcinoma (Wilke
et al., 1999; Lupardus et al., 2000). However, in frogs’pituitary
cells, the inhibitory effects of the selective Sig1R ligand (+) penta-
zocine, on both delayed-rectifier and IA currents, were abolished
in the presence of cholera toxin, GTPγS or GDPβS suggesting the
involvement of a Gs-protein dependent pathway (Soriani et al.,
1998, 1999a). How could these two sets of observation be inter-
preted? In a recent study, Mei et al. showed that the sigma ligand
Cyproheptadine stimulates the Kv2.1-dependent current in cor-
tical neurons in a Sig1R and Gi/o-dependent manner. The study
indeed describes a functional interaction between Sig1R, Kv2.1
and a G-protein coupled receptor (GPCR): the mu-opoid recep-
tor (He et al., 2012). It can then been proposed that sigma ligands,
either alter directly the Sig1R/VGKC coupling or modulate func-
tional complexes that integrate Sig1R, VGKC and GPCR. This last
hypothesis is strengthened by recent reports demonstrating that
Sig1R modulates several GPCR in the brain (i.e. opioid and mus-
carinic acetyl choline receptors) (Kim et al., 2010), and forms
a complex with D1 and D2 dopamine receptors (Navarro et al.,
2010, 2013).
Whether Sig1R requires an endogenous/exogenous sigma lig-
and to modulate VGKC is a crucial question that has been
addressed in a few but important reports focusing on the molecu-
lar interaction between Sig1R and its partners. In Xenopus oocytes,
it has been shown that the co-expression of Sig1R with Kv1.4
or Kv1.3 accelerates the inactivation kinetic parameters (Aydar
et al., 2002; Kinoshita et al., 2012). In human leukaemic cells, our
group found that the silencing of Sig1R by shRNA reduces the
endogenous human ether-à-gogo-related gene (hERG; Kv11.1)
current density without altering channel voltage dependency
or kinetic parameters. Delving into the molecular mechanisms,
we observed that the silencing of Sig1R decreases hERG mat-
uration efficiency and diminishes the α-subunit channel sta-
bility at the plasma membrane, in turn reducing the num-
ber of ion channels available (Crottes et al., 2011). Inasmuch
Sig1R co-immunoprecipitates with hERG, these observations are
consistent with the idea of a Sig1R protein behaving either like
a chaperone or a channel regulatory β-subunit through a pro-
tein/protein interaction (Aydar et al., 2002; Crottes et al., 2011;
Kinoshita et al., 2012). This hypothesis was further strength-
ened by a recent report showing that cocaine exposure induces
in nucleus accumbens a persistent protein/protein association
between Sig-1Rs and Kv1.2 channels. This phenomenon is asso-
ciated with a redistribution of both proteins from the intracel-
lular compartments to the plasma membrane (Kourrich et al.,
2013).
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The presence of VGKC is linked to cell proliferation in var-
ious cancer types, through the regulation of both the resting
(controlling the Ca2+ driving force) and cell volume, both phe-
nomenon participating in the cell cycle checkpoints (for review;
Wulff et al., 2009; Becchetti, 2011; Felipe et al., 2012). The con-
nection between VGKC, Sig1R and cancer cell proliferation has
been first addressed by Renaudo et al. (2004). We observed that
selective Sig1R ligands provoke a cell cycle arrest in small cell
lung carcinoma and T-ALL cells by blocking the delayed-rectifier
and Kv1.3 channels, respectively. In both cases, Sig1R-dependent
inhibition of potassium currents resulted in an accumulation of
the cyclin inhibitor p27Kip1 and a reduction in cyclin A contents,
leading to an arrest at the end of the G1 phase of the cell cycle
(Renaudo et al., 2004).
VGKC of the ether-à-gogo family, i.e., hERG and EAG chan-
nels, represent a source of highly promising therapeutic targets
for cancer. hERG is mainly expressed in the heart, the central
nervous system and the endocrine system were it regulates the
frequency of action potentials (for review: Vandenberg et al.,
2012). In a series of excellent papers, Arcangeli’s group has
demonstrated that hERG is a tumor marker of myeloid and
lymphoid leukaemias, colon and breast carcinoma, ovarian can-
cer and glioblastoma (Pillozzi et al., 2007, 2011; Pillozzi and
Arcangeli, 2010; Arcangeli, 2011). Importantly, they demon-
strated that upon β1 integrin stimulation, hERG forms signal-
ing macro-complexes with β1-integrin, the VEGF receptor Flt-1
or the cytokine receptor CXCR4 in lipid rafts. The channel in
turn participates in a crosstalk between cancer cells and their
microenvironment to promote invasive processes such as motil-
ity, angiogenesis, homing and chemoresistance (Pillozzi et al.,
2007; Pillozzi and Arcangeli, 2010). As stated above, we recently
showed that Sig1R expression stimulates hERG maturation and
membrane stability in the chronic myeloid leukaemia cell line
K562. Inasmuch Sig1R co-immunoprecipitates with both imma-
ture and mature forms of the channel α-subunits, it is sug-
gested that Sig1R not only associates with hERG in the ER, but
also drives it to the plasma membrane (Crottes et al., 2011).
The question of whether Sig1R is involved in the formation of
such hERG-dependent signaling complexes with β-integrins and
other partners is an interesting one but has not been addressed
yet. This hypothesis deserves further consideration in vitro and
in vivo knowing that both Sig1R silencing and treatment with
the sigma ligand igmesine decrease K562 cell adhesion capac-
ity to fibronectin in a hERG-dependent manner (Crottes et al.,
2011).
Channels of the EAG family are present in a number of tumor
types. Stuhmer’s group nicely demonstrated that CHO cells trans-
fected with EAG exhibit a cancerous invasive phenotype in vitro
and in vivo (Hemmerlein et al., 2006; Gomez-Varela et al., 2007;
Pardo and Suhmer, 2008). Further signaling studies revealed that
EAG-1 (Kv10.1) enhances cell resistance to hypoxia by increas-
ing HIF-1 levels, thus stimulating VEGF secretion (Downie et al.,
2008). The over expression of EAG-2 has been recently shown
in human medulloblastoma (MB). In this cancer, EAG-2 pro-
motes the progression of the MB tumor by regulating cell vol-
ume dynamics, in turn inhibiting the tumor suppressor p38
MAPK pathway (Huang et al., 2012). While the putative link
between EAG channels and Sig1R has not been addressed so
far, it is tempting to speculate such an interaction considering
the molecular and structural proximity between EAG and hERG
channels.
2-Voltage-gated Na+ channels (VGNC)
The existence of VGNC has been first speculated by Hodgkin
and Huxley to account for the fast depolarizing phase of the
action potential of excitable cells (Hodgkin and Huxley, 1952). To
date, the family of VGNC includes nine members mainly involved
in the encoding of neuronal signaling, cardiac rhythm, muscle
contraction and endocrine secretion (Hille, 1984; Harmar et al.,
2009). Intriguingly, VGNC are expressed in metastatic cells of
many cancers. In these cells, the sodium current driven by VGNC
α subunits enhances the invasion and metastasis in vivo (Brisson
et al., 2011, 2012; Yang et al., 2012). Expression of the cardiac
Nav1.5 α subunit (SCN5A) is correlated with a poor prognosis
in breast cancer specimens, suggesting that VGSCs may be used
as prognosis marker in cancer progression (House et al., 2010;
Yang et al., 2012). The mechanical link between Nav1.5 and can-
cer progression has been recently documented: in breast cancer
cells, Nav1.5 associates with the Na+/H+ exchanger NHE1 in
caveolae; Nav1.5 stimulates NHE1 activity, contributing to the
acidification of the pericellular space. The low extracellular pH
in turn potentiates the activity of different cathepsins involved
in ECM degradation, a fundamental step for cancer cell inva-
sion process (Gillet et al., 2009; Brisson et al., 2011, 2012). In
recent studies, Jackson and Ruoho’s groups have shown that
sigma ligands reduce Nav1.5-dependent currents in cardiomy-
ocytes of wild type mice. Interestingly, Nav1.5 current sensitivity
to sigma ligands was lost in cardiomyocytes of knock-out mice
for Sig1R (Fontanilla et al., 2009; Johannessen et al., 2011). The
nature of the interaction occurring between Sig1R and Nav1.5
has been scrutinized in 2012 by atomic force microscopy (AFM)
which revealed that Sig1R directly binds the channel with a
four-fold symmetry in human embryonic kidney cell (HEK) het-
erologous expression system (Balasuriya et al., 2012). Because
the Nav1.5 channel includes the four pore-forming α subunits
within a single protein, this result suggests that Sig1R neither
interacts with C- nor N-terminus, but rather with the transmem-
brane domains. This hypothesis is strengthened by the fact that
deletions in the transmembrane domain of Kv1.3 subunits abol-
ish their co-immunoprecipitation with Sig1R in Xenopus oocytes
(Kinoshita et al., 2012). While the suppression of Sig1R expres-
sion in mice cardiomyocytes fails to alter any parameter of the
native Nav1.5 current (Fontanilla et al., 2009), the Sig1R silenc-
ing in the highly aggressive MDA-MB-231 breast cancer cell line
results in a strong reduction in current density, suggesting that
Sig1R controls Nav1.5 trafficking in cancer cells but not in healthy
cardiac cells (Balasuriya et al., 2012). From these observations,
it can be hypothesized that Sig1R, by enhancing Nav1.5 mem-
brane expression in breast cancer cells, modulates NHE1 activity,
resulting in greater aggressiveness potency.
3-Voltage-gated calcium channels (VGCC)
VGCC are principally involved in fast synaptic transmission,
cardiomyocyte and striated muscle contraction, as well as
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stimulus-secretion coupling. The low threshold T-type channel
(Cav-3) has however been involved in proliferation and differenti-
ation in several cancer cell lines (Gackiere et al., 2008; Prevarskaya
et al., 2010; Becchetti, 2011). While no data support an inter-
action between Sig1R and the T-type channel in the literature,
it has been shown that Sig1R co-immunoprecipitate with high-
threshold L-type channels in retinal ganglion and that the sigma
ligand SKF 10.047 inhibits the corresponding current (Tchedre
et al., 2008). These observations suggest that VGCC in cancer cells
might be a client for Sig1R.
CALCIUM-ACTIVATED POTASSIUM CHANNELS (KCa)
KCa channels are involved in many physiological processes by
regulating calcium entry through the control of the mem-
branes’resting potential and Ca2+ driving force. A link between
Sig1R and small-conductance KCa channels has been recently
proposed in synaptic activity and plasticity in the hippocampus
(Martina et al., 2007). In this report, the authors showed that
Sig1R ligands potentiate the N-Methyl-D-Aspartate (NMDA)
receptor responses and long-term potentiation (LTP) by inhibit-
ing a small conductance Ca2+-activated K+ current (SK channel).
Interestingly, SK3 channels play a predominant role in melanoma
and breast cancer cell migration and are considered as potent
targets for cancer therapy (Potier et al., 2006; Chantome et al.,
2009; Girault et al., 2012). On the other hand, SK4 channels have
been involved in the migration potency of glioblastoma stem cells
(Ruggieri et al., 2012). The putative interaction between SK chan-
nels and Sig1R thus constitutes an interesting hypothesis that
remains to be explored.
VOLUME-REGULATED CHLORIDE CHANNELS (VRCC)
VRCC, functionally coupled with K+ channels, drive cell volume
regulation by controlling chloride salt-associated water efflux
(Hoffmann et al., 2009). Cell volume regulation and regulatory
volume decrease (RVD) participate to at least three main aspects
of cancer progression, i.e., cell cycle (G1/S and G2/M volume
checkpoints) (Lang et al., 2000; Rouzaire-Dubois et al., 2000;
Becchetti, 2011; Hoffmann, 2011; Huang et al., 2012), motility
(control of cell shape dynamics through salt and water fluxes)
(Cuddapah and Sontheimer, 2011) and apoptosis (Apoptosis
Volume Decrease occurring at an early signaling step of pro-
grammed cell death) (Bortner and Cidlowski, 2011; Bortner et al.,
2012). Our group has shown that sigma ligands strongly inhibit
both VRCC and VGKC in T leukaemic and small cell lung car-
cinoma cells in a Sig1R-dependent manner. VRCC and VGKC
inhibition lead to a strong reduction in RVDpotency after a hypo-
tonic shock. In isotonic conditions, cell treatment with sigma
ligands lead to cell swelling, underlying an arrest of cell division
at the late G1 phase. These results indicate that the pharmacolog-
ical alteration of Sig1R, by inhibiting channels involved in RVD,
can block the cell division process (Renaudo et al., 2004, 2007).
In these studies we also questioned the function of Sig1R in can-
cer cells in the absence of exogenous ligands. We observed that
the over-expression of Sig1R in HEK cells was sufficient per se to
significantly reduce the activation kinetics of VRCC upon hypo-
tonic shock. We proposed that the presence of Sig1R induces a
tonic reduction of VRCC activity, not sufficient to impede the
cell cycle, but strong enough to protect cells from apoptosis by
delaying AVD. This result was confirmed by showing that cells
over-expressing Sig1R are less sensitive to staurospaurine-induced
apoptosis than normal cells (Renaudo et al., 2007). Together with
other reports, this study has unveiled the function of Sig1R as a
protein involved in cell protection against environmental stress by
modulating ion channels (Hayashi and Su, 2007; Renaudo et al.,
2007).
CALCIUM SIGNALING AND ION CHANNELS AT THE MAM
Cell fate largely depends on calcium exchanges occurring between
ER and mitochondria. These exchanges generally take place at
specific membrane localization, the MAMs, which were orig-
inally described as sites for lipid synthesis and lipid transfer
between ER and mitochondria membranes (Rusinol et al., 1994)
for review: (Parys et al., 2012). Calcium fluxes between the two
compartments involve various chaperones and signaling proteins
as well as ion channels and transporters including IP3 receptors,
voltage-dependent anion channels (VDAC) or the translocon.
The regulation of calcium entry in the mitochondria participates
in the control of the energy state and cell response to ER-mediated
stress. Calcium homeostasis at MAM therefore constitutes a
crossroad decision for cell engagement toward apoptosis, survival
or autophagy (Tsai et al., 2009; Parys et al., 2012; Hammadi et al.,
2013). Not surprisingly, MAM-associated transport machinery is
disregulated in the context of environmental challenges in can-
cer such as hypoxia, low pH and dramatic nutrient deprivation
(Moenner et al., 2007; Raturi and Simmen, 2013). As stated above,
Hayashi and Su have demonstrated in CHO cells that the Sig1R
chaperone plays a fundamental role in regulating the Ca2+ trans-
port machinery within the MAMs, leading to a reinforced cell
survival in response to environmental stress (Hayashi and Su,
2007). In particular, stress-activated Sig1R chaperones IP3 recep-
tor and prevents its degradation. Moreover a recent report has
shown that Sig1R is physically associated to VDAC2, a mitochon-
drial channel involved in cholesterol import into the mitochodria
for metabolic regulation (Marriott et al., 2012). While no data is
available on the function of MAM-associated Sig1R in tumors, it
is conceivable that Sig1R contributes to the adaptation of cancer
cells in restrictive environment.
CONCLUSION AND PERSPECTIVES
In summary, Sig1R is a stress-activated chaperone which controls,
through different mechanisms, several families of ion channels
at the plasma membrane and at the MAM. Studies realized in
the retina, brain and heart strongly suggest that Sig1R partici-
pates in cell resistance to tissue injury, for instance infarction,
stroke or ischemia (Kourrich et al., 2012). Several reports indi-
cate that Sig1R exerts a role only in conditions of stress and
remains generally “silent” in healthy organs or in steady-state
conditions (Maurice and Su, 2009; Tsai et al., 2009). In good
agreement with this idea, Sig1R KO mice present a normal devel-
opment and behavior but are less resistant to experimental stroke
(Ruscher et al., 2011). Moreover, the absence of side effects of
Sig1R ligands in clinical trials in human suffering psychiatric dis-
orders, improves the hypothesis of a dynamic and protective role
of Sig1R in stressing conditions (Volz and Stoll, 2004; Banister
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and Kassiou, 2012). Thus, it is tempting to speculate that tumor
cells hijack the primary protective function of Sig1R to enhance
their survival/growing/invasive potency in restrictive metabolic
conditions encountered within the tumor tissue. As demonstrated
by many authors, the aberrant expression of ion channels con-
fers selective advantages for cancer cells to adapt their behavior
and survival in the tumor environment. While research studies
mainly focus on the function of one ion channel in a cancer
type, it is important to consider that many ion channels are
deregulated in the same cancer cell. Because a variety of ion chan-
nels are client proteins for Sig1R, we speculate that the Sig1R
chaperone controls cancer cells’electrical plasticity by putatively
“driving” ion channels to potentiate their function in prolifera-
tion, apoptosis resistance, migration and angiogenesis (Figure 2).
At the time being, there is no real explanation on the pro-
cess that controls the expression of all these ion channels in
cancer cells and it is often postulated that this is due to the
acquisition of an embryonic or developmental phenotype. The
possibility that Sig1R expression might participate to this phe-
notype is an interesting hypothesis that has not been explored
so far.
The literature strongly argues for a close interaction between
Sig1R and ion channels that are already expressed in the cell. An
alternative mechanism should however be considered: because
FIGURE 2 | Schematic diagram summarizing putative and documented
interactions between Sig1R and ion channels in cancer cells. Sig1R
promotes hERG maturation and membrane stability which may potentiate
channel interaction with β1 integrin macrocomplexes, leading to enhanced
migration and angiogenesis. Sig1R also directly binds to other VGIC such as
Kv1.3, Kv1.5, and Nav1.5 controlling either current density or kinetic
properties of channels. These interactions may have consequences on cell
proliferation, apoptosis resistance, chemoresistance and invasive properties.
The presence of Sig1R in cancer cells tonically reduces VRCC activity via a
yet unknown mechanism, leading to a better resistance to apoptotic signals.
Sigma receptors have also been associated to SK channels, suggesting that
they may participate to cancer cell motility. At the MAM, Sig1R may enhance
cell survival by regulating calcium fluxes between ER and mitochondria by
chaperoning IP3 receptors and VDAC channels.
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of the spatial dynamics of Sig1R within the cell, the protein could
also behave as a transcriptional factor controlling either directly
or indirectly a kit of genes encoding ion channels. While no
data supports the presence of Sig1R in the nucleus, many reports
have shown the involvement of Sig1R in a number of signal-
ing pathways potentially targeting transcriptional activity (i.e.,
MAP kinases, PKA, PI3K/AKT, NFk-B, c-Fos, CREB) (for review:
Hayashi et al., 2011).
It is noteworthy that ion channels expressed in cancer cells
play important functions in healthy organs as well such as in
the heart and brain. As a consequence, therapies based on toxins
and drugs directly targeting ion channels present major draw-
backs for cancer treatment. The unique properties of Sig1R
may pave a new avenue to alter ion channels specifically within
tumors. In this regard, many outstanding questions need to be
addressed to unravel the importance of Sig1R in cancer such as
the consequences of Sig1R silencing on the electrical signature of
cancer cells and subsequent alteration of their behavior in vitro
and in vivo. Promising anti-tumoral effects have been obtained
in vivo with exogenous sigma ligands, but the innate function of
Sig1R in cancer remains undetermined. Moreover, the molecu-
lar mechanisms of Sig1R ligands on Sig1R/ion channel complexes
remain to be addressed.
Answers to these questions will open new strategies based on
the targeting of Sig1R to target ion channels and associated cancer
progression.
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